Shi Ming

Shiming Biotech is a China-based biotechnology company focused on the development of next-generation antibody-drug conjugates (ADCs) for the treatment of various cancers. The company utilizes a proprietary site-specific conjugation technology platform designed to produce highly stable and homogeneous ADC candidates with improved therapeutic indices compared to traditional conjugation methods. Shiming's pipeline primarily targets validated oncology markers such as HER2 and TROP2, aiming to address unmet needs in solid tumor indications. By optimizing the linker-payload chemistry and conjugation sites, the company seeks to minimize off-target toxicity while maximizing anti-tumor efficacy.